Cagrilintide Dosage Chart: A Programme Still in Progress
Where the development sequence has reached, and the step it has not yet taken.
Cagrilintide is at a stage most compounds discussed on this site never reach, and it is worth being precise about which stage, because the difference between late-stage and approved is where most misreadings happen.
Stage reached: a large Phase 3 programme
ClinicalTrials.gov lists roughly 45 studies. Twenty-two are Phase 3, seventeen Phase 1, six Phase 2. Around 25 are recorded as completed, with ten recruiting and seven active but not recruiting.
That is what a real development programme looks like from the outside: dose-finding completed, late-stage efficacy work under way, and a schedule that has been running for years.
One detail the counts do not show
Every one of those studies lists Novo Nordisk as lead sponsor. Not one independent or academic entry appears anywhere in the registry.
That cuts both ways. A company running 22 Phase 3 studies is not speculating, and the expense is itself evidence of seriousness. It also means the whole evidence base has a single owner and nobody outside it has replicated anything, which is ordinary during development and still worth stating when figures leave the programme.
Stage not reached: approval
No regulator has approved cagrilintide. There is no label, no authorised quantity, and nobody outside the sponsor accountable for a number.
That is the distinction a cagrilintide dosage chart has to carry. Trial quantities are real, measured and published, and restating them is legitimate. Presenting them as a dose implies an authorisation that has not been granted.
The combination question, stated carefully
The registered programme pairs cagrilintide with semaglutide, as CagriSema. Searches often ask about cagrilintide with tirzepatide instead, which is a different pairing and not what these trials examined.
Quantities from one combination do not transfer to another. The two partner drugs differ in mechanism, in half-life and in titration schedule, and a figure established alongside one says nothing about the other.